Lundbeck and Otsuka announce topline results from two phase III trials of brexpiprazole as combination therapy with sertraline for the treatment of Post-Traumatic Stress Disorder in adults
· The flexible dose phase III trial met its primary endpoint, while the fixed dose phase III trial missed its primary endpoint · Lundbeck and Otsuka will discuss these results with FDA to determine next steps Valby, Denmark, September 7, 2023 – H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced results from the phase III clinical trials of brexpiprazole as combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD) in adults. The first trial (NCT04124614) was a phase III, randomized, double-blind, 2-arm,